In Alzheimer’s disease (AD), personalized medicine helps predict risk and guide targeted treatments through APOE ε4 and other genetic variants, while in Parkinson’s Disease (PD), mutations in the GBA and LRRK2 genes influence disease course and therapy response. Here, LRRK2 is linked to Alzheimer disease.